Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib

Since the introduction of immune modulators in the treatment of rheumatoid arthritis (RA), there has been hope that orally effective biologic agents would be developed. Tofacitinib, a Janus kinase inhibitor, has become the first oral biologic to receive approval for use in active RA patients. This p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Han, Moe, Soe, Myint, Kay Thi, Htet, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736471/
https://www.ncbi.nlm.nih.gov/pubmed/23970975
http://dx.doi.org/10.1155/2013/357904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736471/
https://www.ncbi.nlm.nih.gov/pubmed/23970975
http://dx.doi.org/10.1155/2013/357904

Ejemplares similares